Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 03, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $92.8 million, representing 17% growth over the prior year quarter Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows...
Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting
November 02, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Late-breaking oral presentation compares transplant-free survival in patients with PBC treated with OCA to external controls from the Global PBC and UK-PBC study groups Poster presentations describe...
Intercept to Announce Third Quarter 2021 Financial Results on November 3, 2021
October 27, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 21, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Pharmaceuticals Announces Convertible Notes Repurchase
September 13, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference
September 01, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
August 10, 2021 21:43 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
July 29, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to...
Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021
July 19, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021
June 21, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in patients with fibrosis due to NASH treated with...